Celltrion receives European Commission approval of Omlyclo ® (CT-P39), the first and only omalizumab biosimilar approved in Europe
Celltrion today announced that the European Commission (EC) has approved Omlyclo® (CT-P39), an omalizumab biosimilar referencing Xolair®. Omlyclo® is approved for the treatment of allergic asthma, chronic spontaneous urticaria (CSU), and chronic rhinosinusitis with nasal polyps (CRSwNP).
The EC approval of Omlyclo® follows the recommendation for marketing authorisation issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in March 2024.
The decision is based on clinical evidence, including results from a global Phase III clinical trial designed to evaluate the efficacy, safety and pharmacokinetics of Omlyclo® compared to the reference product Xolair® in patients with CSU up to Week 40.
“For more than two decades, omalizumab, a blockbuster monoclonal antibody anti-IgE, has revolutionised the management of chronic immune-mediated inflammatory diseases,” said Professor Marcus Maurer, Professor of Dermatology and Allergy, Co-Director for the Fraunhofer Site for Immunology and Allergology of the Fraunhofer Translational Medicine and Pharmacology ITMP and Executive Director for the Institute of Allergology, Charité - Universitätsmedizin Berlin, Germany. “The development of a biosimilar of omalizumab is a welcome solution to help alleviate some challenges with treatment access. The recently approved treatment Omlyclo® has a comparable efficacy, safety and immunogenicity profile to Xolair®.”
“Immunological conditions such as asthma can have a significant impact on the day-to-day lives of patients without appropriate treatment and care. This is why we are pleased to receive the first EC approval for an omalizumab biosimilar in Europe, an important step towards improving patient access to treatment. As we continue to expand our biosimilar offerings across the globe, building on our immunology and oncology product portfolio, we look forward to making a meaningful difference for patients living with immunological conditions,” said Hyoung-Ki Kim, Vice Chairman at Celltrion.
Omlyclo® is Celltrion’s sixth biosimilar, besides Remsima® SC, a subcutaneous formulation of infliximab, approved for use in the EU, following the approval of Remsima® (biosimilar infliximab), Truxima® (biosimilar rituximab), Herzuma® (biosimilar trastuzumab), Yuflyma® (biosimilar adalimumab), and Vegzelma® (biosimilar bevacizumab). Omlyclo® is currently under review by the U.S. Food and Drug Administration (FDA), following the submission in March 2024.
About OMLYCLO® (CT-P39, biosimilar omalizumab)
Omlyclo® is the first European Commission (EC) approved anti-IgE antibody biosimilar referencing Xolair® (omalizumab). In the EU, Omlyclo® is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP).
About Celltrion
Celltrion is a leading biopharmaceutical company based in Incheon, South Korea that specialises in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. The company’s solutions include world-class monoclonal antibody biosimilars such as Remsima®, Truxima® and Herzuma®, providing broader patient access globally. Celltrion has also received U.S. FDA and EC approval for Vegzelma® and Yuflyma®, FDA approval for Zymfentra™, and EC approval for Remsima® SC. To learn more, please visit www.celltrion.com/en-us.
FORWARD-LOOKING STATEMENT
Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws.
These statements may be identified by words such as “prepares”, “hopes to”, “upcoming”, ”plans to”, “aims to”, “to be launched”, “is preparing, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, the negative of these words or such other variations thereon or comparable terminology.
In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion Inc. and its subsidiaries' management, of which many are beyond its control.
Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.
Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this presentation are based upon what management of Celltrion Inc. and its subsidiaries believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Celltrion Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
Trademark
Xolair® is a registered trademark of Novartis AG.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521556727/en/
Contact information
Holly Barber
hbarber@hanovercomms.com
+44 (0) 7759 301620
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Curiosity Cube 2025: Merck’s Mobile Science Labs Tour Globally to Bring STEM Education to Students24.4.2025 14:00:00 CEST | Press Release
Merck, a leading science and technology company, today launched its global 2025 Curiosity Cube tour in Darmstadt, Germany. The solar-powered mobile science labs will bring hands-on STEM (science, technology, engineering and mathematics) experiences to students across Europe, North America, and for the first time, Africa. In 2025, the tour aims to reach 60,000 students worldwide. The initiative underscores Merck's commitment to inspiring enthusiasm for science and technology. Merck today also opened its Curiosity Labs™ STEM Center in Darmstadt with 11 interactive science lessons to complement the Curiosity Cube experience for local students year-round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424271266/en/ The mobile science labs tour Europe, North America and for the first time, Africa. “With technological advances and scientific breakthroughs reshaping the world, it has never been more important to inspire early in
UPS to Acquire Andlauer Healthcare Group for $1.6 Billion, Strengthening its Global Offerings in Complex Healthcare Logistics24.4.2025 13:30:00 CEST | Press Release
UPS(NYSE: UPS) today announced that it has entered into a definitive agreement to acquire Andlauer Healthcare Group Inc. (TSX: AND) (“AHG”), a leading North American supply chain management company headquartered in Canada and offering customized third-party logistics and specialized cold chain transportation solutions for the healthcare sector. Under the terms of the agreement, AHG shareholders will receive CAD $55.00 per share in cash, representing a total purchase price of approximately CAD $2.2 billion (USD $1.6 billion). This transaction will extend the global portfolio of end-to-end cold chain capabilities available to UPS Healthcare customers, who increasingly seek temperature-controlled and precision logistics solutions. “Next-generation treatments are driving more complexity than ever, expanding the needs of healthcare customers and increasing demand for the integrated, end-to-end cold chain solutions UPS Healthcare provides around the world,” said Kate Gutmann, EVP and preside
MSCI Expands Private Assets Toolkit With Launch of Indexes Tracking Venture-Backed Companies24.4.2025 13:00:00 CEST | Press Release
MSCI Inc. (NYSE: MSCI) has launched two MSCI All Country Venture-Backed Private Company Indexes, advancing the firm’s commitment to empowering investors with clear, transparent insights on the performance of private assets globally. With these indexes, MSCI is applying decades of index construction expertise to calculate the performance of venture-backed private company shares based on secondary market transaction data. Private companies that receive funding from venture capital investors often operate in high-growth, technology-driven industries that have garnered growing interest from investors and wealth managers in recent years. While such companies do not trade on centralized exchanges, over-the-counter secondary markets play a key role in providing liquidity and facilitating price discovery. Venture-backed companies are staying private for longer periods, with the number of publicly listed companies in the US dropping by nearly half between 1996 and 2022.1 The number of private v
Aztec Group and Lantern Form a Strategic Alliance to Elevate Fund Data Access and Client Experience in Private Markets24.4.2025 11:16:00 CEST | Press Release
Private markets are at a tipping point – the demand for streamlined, accessible fund data is growing rapidly, driven by General Partners (GPs) and investors who expect greater transparency, speed, and collaboration. In response, Aztec Group, a leading fund and corporate services provider, has partnered with Lantern, an innovative data intelligence platform, to enhance how clients can access high-quality, on-demand fund data and enable data-driven decision-making. Will Relf, Director of Data at Aztec commented: “As the industry continues to evolve, access to high-quality, timely data is no longer a luxury - it’s a necessity. At Aztec, we are committed to ensuring our clients can operate with confidence, backed by trusted data. Working with Lantern further enhances our ability to provide clients with innovative solutions for on-demand fund data, fully integrated with our accounting records and other key data sources.” By utilising Lantern as a component of its broader data offering, Azte
Aqualung Carbon Capture Successfully Closes Phase 1 2025 Financing Round24.4.2025 10:33:00 CEST | Press Release
Aqualung Carbon Capture (“Aqualung”), a pioneering leader in membrane carbon dioxide (CO2) capture and separation technology, is excited to announce the successful first close of its funding round. This round is backed by Aqualung’s Joint Development Agreement (JDA) partner, one of the largest global membrane manufacturers, along with other strategic investors including Liquid Gas Equipment Ltd (LGE), wholly owned by Babcock International Group, Tupras Ventures, and Delek Innovation, the CVC of Delek (US) Holdings. This capital raise represents a significant milestone in Aqualung’s mission to establish itself as a leading carbon capture company. Over the past four years, Aqualung’s pilot units have successfully demonstrated its innovative non-pressurized facilitated transport membrane solution to be cost effective and applicable across various industries, including natural gas processing, lime kilns, and waste-to-energy applications. These units will continue to underpin the commercial
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom